drugset / Trial / NCT03713372
Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma
Phase 2
Unknown
40 enrolled
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma after failure of platinum-based therapy.
Timeline
- Start
- 2018-11-28
- Primary completion
- 2020-02-11
- Completion
- 2020-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCT200 | Monoclonal antibody | 8 mg/kg | — |